Clinical trials
Colorectal clinical trials
Below are recruiting colorectal clinical trials, each written for real people, not researchers. We’re tracking 1,204 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06680739RecruitingPhase 2
Study of immunotherapy for colorectal and endometrial cancer
This trial tests two immunotherapy drugs, durvalumab and tremelimumab, in people with colorectal or endometrial cancer that has spread or come back. The goal is to understand why some tumors persist or don't respond to treatment.
BarcelonaAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT06696534Recruiting
Patient views on colorectal cancer screening methods
This study asks people aged 50–69 about their experience and preferences with different screening methods for colorectal cancer. It aims to improve screening programs by understanding what patients prefer.
LisbonAges 50–69 - NCT07345676Recruiting
Helping patients complete colorectal cancer screening
This trial is testing a simple program to help people who are due for colorectal cancer screening to complete their test. It's for patients at Cornell Scott Hill Health who either haven't finished a screening order or had an abnormal stool test without follow-up.
New Haven, ConnecticutAges 45–75 - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT07107230RecruitingPhase 1
Study of JNJ-95437446 for advanced solid tumors
This trial tests a new drug, JNJ-95437446, in people with certain advanced cancers (non-small cell lung, colorectal, or head and neck cancer). The goal is to see if it can help shrink or control the cancer.
Sarasota, FloridaAges 18 years+ - NCT07224841Recruiting
Blood test to predict targeted therapy response in colorectal cancer
This study is developing a blood test that looks at DNA signals to see if certain targeted therapies will work for people with metastatic colorectal cancer. It may help doctors choose the right treatment in the future.
Duarte, CaliforniaAges 18 years+ - NCT07224750Recruiting
A blood test to find early signs of gastrointestinal cancer
This study is testing a blood-based test to detect unique molecules (called miRNAs) that may signal the presence of several types of gut or digestive system cancers. The goal is to develop a simple screening tool that could catch these cancers earlier.
Duarte, CaliforniaAges 18 years+ - NCT06710756RecruitingPhase 1/Phase 2
Lead-212 therapy for solid tumors
This trial tests a new radioactive drug, Lead-212 PSV359, for people with advanced solid tumors that have not responded to standard treatments. The drug is designed to find and attack cancer cells.
Miami, FloridaAges 18–90 - NCT06710067Recruiting
Urine chemicals for diagnosing disease
This study looks at chemicals in urine to help find new ways to diagnose diseases. You give one urine sample and answer a few questions—no treatment or long-term follow-up needed.
Encinitas, CaliforniaAges 18 years+ - NCT06711211Recruiting
Digestive cancer registry study
This study collects information from patients with different types of digestive cancers to better understand these diseases and improve future care. It does not test a new treatment, but helps doctors learn more about digestive cancers over time.
Madrid, MadridAges 18 years+ - NCT06717295Recruiting
Blood test to find cancer early and track treatment
This study uses a blood test that looks at your platelets and immune cells to find common cancers early, and for certain cancers, to monitor how well treatment is working.
RosarioAges 40–75 - NCT06719206Recruiting
Reducing sitting time during cancer treatment
This study looks at helping people with breast, prostate, or colorectal cancer who are starting or have recently started treatment (like chemo or radiation) to sit less and move more during their treatment. If you are treated at a hospital in Uppsala or Västerås, Sweden, you may be able to join.
UppsalaAges 18 years+ - NCT06720987RecruitingPhase 1
KQB365 for advanced solid tumors with KRAS mutations
This trial tests a new drug called KQB365, alone or with other drugs, for people with advanced solid tumors that have a specific KRAS mutation (G12C or G12S). It aims to see if the treatment is safe and effective.
Phoenix, ArizonaAges 18 years+ - NCT06723236RecruitingPhase 1
Study of MGC028 for Advanced Solid Tumors
This study tests a new drug called MGC028 for people with certain advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and effective.
San Francisco, CaliforniaAges 18 years+ - NCT06731998Recruiting
Improving pain control after cancer surgery
This study compares different methods of managing pain after minimally invasive surgery for abdominal cancers. It aims to find which approach works best to reduce pain and improve recovery.
Pittsburgh, PennsylvaniaAges 18–89 - NCT06746012Recruiting
Health app study for colorectal cancer survivors and their caregivers
This study tests a mobile health program to help colorectal cancer survivors and their family caregivers stick to healthy lifestyle habits. It's for survivors who are at least 6 months past treatment and have a smartphone.
Columbus, OhioAges 18 years+ - NCT06751914Recruiting
Vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751940Recruiting
Personalized vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Nanchang, JiangxiAges 18–70 - NCT06751953Recruiting
Neoantigen vaccine plus standard third-line therapy for colorectal cancer
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06751966Recruiting
Peptide vaccine plus standard therapy for advanced colorectal cancer
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
Nanchang, JiangxiAges 18–70 - NCT06756035RecruitingPhase 1
Testing CT-95 in advanced cancers with mesothelin
This trial tests a new drug (CT-95) for advanced cancers that have a marker called mesothelin. It's an early-phase study to see if the drug is safe and effective.
Denver, ColoradoAges 18 years+ - NCT06765252Recruiting
How gene differences affect capecitabine side effects
This study looks at how genetic differences in Egyptian people with breast or colorectal cancer might affect the side effects of the chemotherapy drug capecitabine. The goal is to understand why some people have more side effects than others.
Shibīn al Kawm, MenoufiaAges 18 years+ - NCT06765616RecruitingPhase 2
Immunotherapy with chemo and radiation for rectal cancer before surgery
This trial tests a combination of a PD-L1 inhibitor (adebrelimab), short-course radiation, and chemotherapy given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes.
Jinan, ShandongAges 18–85
Hear when a new Colorectal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal?
- Yes. Clin2 currently lists 1,204 recruiting colorectal studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.